686267-34-5

Usage

InChI:InChI=1/C13H13N3O2S/c1-19-13-15-8-10(12(17)18)11(16-13)14-7-9-5-3-2-4-6-9/h2-6,8H,7H2,1H3,(H,17,18)(H,14,15,16)

Upstream product

• 686266-25-1 methyl 4-[(2-ethylbutyl)amino]-2-(methylthio)pyrimidine-5-carboxylate 
• 100973-67-9 ethyl 4-(benzylamino)-2-(methylthio)pyrimidine-5-carboxylate 
• 100-46-9 benzylamine 
• 5909-24-0 4-chloro-2-methanesulfanylpyrimidine-5-carboxylic acid ethyl ester 

Downstream Products

• 1430095-86-5 4-((4-(benzylamino)-5-carbamoylpyrimidin-2-yl)amino)phenyl methanesulfonate 
• 1430096-00-6 4-((4-(benzylamino)-5-carbamoylpyrimidin-2-yl)amino)phenyl propane-2-sulfonate 
• 1430095-89-8 4-((4-(benzylamino)-5-carbamoylpyrimidin-2-yl)amino)-2-(dimethylamino)phenyl methanesulfonate 
• 1254213-18-7 4-(benzylamino)-2-(methylsulfinyl)pyrimidine-5-carboxamide 
• 686267-35-6 1-benzyl-7-(methylthio)-2H-pyrimido[4,5-d][1,3]oxazine-2,4(1H)-dione 
• 453563-01-4 N-[4-(isopropyl)-phenyl]{2-methylthio-4-[(4-pyridylmethyl)-amino]-pyrimidin-5-yl}-carboxamide 
• 919486-40-1 AS 1517499 
• 643086-98-0 4-(benzylamino)-2-(methylsulfonyl)pyrimidine-5-carboxamide 
• 919486-28-5 4-(benzylamino)-N-methyl-2-(methylsulfonyl)pyrimidine-5-carboxamide 
• 919486-27-4 4-(benzylamino)-N-methyl-2-(methylsulfanyl)pyrimidine-5-carboxamide 
• 919486-26-3 4-(benzylamino)-2-(methylsulfanyl)pyrimidine-5-carboxamide 

Relevant academic research and scientific papers

Discovery of diaminopyrimidine-carboxamide derivatives as JAK3 inhibitors

Selective inhibition of janus kinase (JAK) has been identified as an important strategy for the treatment of autoimmune disorders. Optimization at the C2 and C4-positions of pyrimidine ring of Cerdulatinib led to the discovery of a potent and orally bioavailable 2,4-diaminopyrimidine-5-carboxamide based JAK3 selective inhibitor (11i). A cellular selectivity study further confirmed that 11i preferentially inhibits JAK3 over JAK1, in JAK/STAT signaling pathway. Compound 11i showed good anti-arthritic activity, which could be correlated with its improved oral bioavailability. In the repeat dose acute toxicity study, 11i showed no adverse changes related to gross pathology and clinical signs, indicating that the new class JAK3 selective inhibitor could be viable therapeutic option for the treatment of rheumatoid arthritis.

INHIBITORS OF JAK

The present invention is directed to compounds of formula (I) and tautomers and pharmaceutically acceptable salts thereof which are selective inhibitors of JAK. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition JAK activity, and methods to prevent or treat a number of conditions mediated at least in part by JAK activity.

AMIDE COMPOUNDS AND USE OF THE SAME

A renin inhibitor comprising a compound represented by the formula: wherein each symbol is as defined in the description, or a salt thereof or a prodrug thereof. The compound of the present invention has a superior renin inhibitory activity, and thus is useful as an agent for the prophylaxis or treatment of hypertension, various organ damages attributable to hypertension and the like

Synthesis and evaluation of 2-{[2-(4-hydroxyphenyl)-ethyl]amino}pyrimidine-5-carboxamide derivatives as novel STAT6 inhibitors

The STAT6 (signal transducers and activators of transcription 6) protein is activated by interleukin (IL)-4 and IL-13, and plays an important role in T-helper cell 2 (Th2) differentiation. STAT6 might therefore be an excellent therapeutic target for various allergic conditions, including asthma and atopic diseases. We synthesized a series of 2-{[2-(4-hydroxyphenyl)ethyl]amino}pyrimidine-5-carboxamide derivatives and evaluated their STAT6 inhibitory activities. Among these compounds, 4-(benzylamino)-2-{[2-(3-chloro-4-hydroxyphenyl)ethyl]amino}pyrimidine-5-carboxamide (2t, AS1517499) showed potent STAT6 inhibition with an IC50 value of 21 nM, and also inhibited IL-4-induced Th2 differentiation of mouse spleen T cells with an IC50 value of 2.3 nM and without influencing T-helper cell 1 (Th1) differentiation induced by IL-12.

Anti-infective agents

Compounds having the formula are hepatitis C(HCV) polymerase inhibitors. Also disclosed are a composition and method for inhibiting hepatitis C(HCV) polymerase, processes for making the compounds, and synthetic intermediates employed in the processes.

Anti-infective agents

Compounds having the formula are hepatitis C (HCV) polymerase inhibitors. Also disclosed are a composition and method for inhibiting hepatitis C (HCV) polymerase, processes for making the compounds, and synthetic intermediates employed in the processes.

Substituted alkylamine derivatives and methods of use

Selected amines are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.